InnoCare Pharma announced the approval of tafasitamab in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT) by the Department of Health, the Hong Kong Special Administrative Region, China.
Dr. Jasmine Cui, co-founder, chairwoman and CEO of InnoCare, said,
